Compare · AZN vs LFCR
AZN vs LFCR
Side-by-side comparison of AstraZeneca PLC (AZN) and Lifecore Biomedical Inc. (LFCR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and LFCR operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $261.92B, about 1492.0x LFCR ($175.5M).
- Over the past year, AZN is down 10.3% and LFCR is down 37.2% - AZN leads by 26.9 points.
- AZN has been more active in the news (12 items in the past 4 weeks vs 2 for LFCR).
- AZN has more recent analyst coverage (25 ratings vs 6 for LFCR).
- Company
- AstraZeneca PLC
- Lifecore Biomedical Inc.
- Price
- $168.85-0.24%
- $4.68-5.26%
- Market cap
- $261.92B
- $175.5M
- 1M return
- -5.56%
- -12.85%
- 1Y return
- -10.32%
- -37.18%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- News (4w)
- 12
- 2
- Recent ratings
- 25
- 6
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 11-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest LFCR
- Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Lifecore Biomedical Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company
- Director Kiper Christopher S was granted 25,907 shares (SEC Form 4)
- Director Obus Nelson was granted 25,907 shares, increasing direct ownership by 19% to 164,100 units (SEC Form 4)
- Director Aryeh Jason was granted 25,907 shares, increasing direct ownership by 59% to 69,967 units (SEC Form 4)
- Director Korenberg Matthew E was granted 25,907 shares, increasing direct ownership by 59% to 69,967 units (SEC Form 4)
- Director Schechter Joshua was granted 25,907 shares, increasing direct ownership by 24% to 133,080 units (SEC Form 4)
- Director Antunes Humberto Calheiros was granted 25,907 shares, increasing direct ownership by 55% to 72,967 units (SEC Form 4)
- Director Johnson Paul Harold was granted 25,907 shares, increasing direct ownership by 59% to 69,967 units (SEC Form 4)